

MDS UK PATIENT SUPPORT GROUP

(A charitable company limited by guarantee)

Unaudited Financial Statements

Year ended 31st March 2017

Registered Company Number: 07818480

Registered Charity Number: 1145214

MDS UK PATIENT SUPPORT GROUP

Index

Page Number	Description
3 to 8	Report of the Directors
9	Unaudited Statement of Financial Activities
10	Unaudited Balance Sheet
11 to 13	Unaudited Notes to the Financial Statements

Registered Company Number: 07818480

Registered Charity Number: 1145214

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

The Directors, who are also trustees, submit their report together with the financial statements for the year ended 31st March, 2017.

Results

The results for the year and the financial position of the company ("MDSUK") are shown in the annexed financial statements. The company is a non-profit distributing company limited by guarantee and is a registered charity (No, 1145214).

The financial statements have been prepared in accordance with the accounting policies and comply with the Charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102). The Charity has taken advantage of the exemption in Financial Reporting Standards from producing a cash flow statement on the grounds that it is entitled to the exemption for smaller companies available in Section 38 of the Companies Act 2006.

Chair's Report

Unfortunately, during this year our Charity lost its Chair of long standing, Professor Rodney Taylor when he finally succumbed to MDS. Rodney had led the Charity as Chair for several years, during which he had helped establish the MDS Support Group as a leading light in publicising the needs and concerns of MDS sufferers in both the United Kingdom and Europe. He was much respected by clinicians, pharmaceutical companies and, of course, those suffering from MDS and will be sorely missed.

This year has seen the Charity taking further steps to identify the skills required within the Management Committee in order to formulate a more strategic approach to leading the Charity. A first step was to designate a dedicated Fund Raising Team and it is hoped to establish similar functional teams for matters such as Technical Support, External Communications, Publicity and Patient Support. An additional Management Committee meeting has been added to the annual calendar that will be dedicated to fund raising and led by the Head of the new Fund Raising Team. Several new members have been appointed to the Management Committee and it is hoped that the changes will introduce a more dynamic approach to management.

A Constitution is also being prepared by the new incumbent Chair which will assist all in understanding not only our aims and aspirations but also the obligations and responsibilities of those working for the Charity. It will also detail some legal necessities, introduce terms of service and selection processes for those acting for the Charity and lay down specific responsibilities for Trustees. It is intended that this new constitution will become a reference document for MDS Patient Support Group in the future.

MDS UK is extremely grateful for the support it receives from all its donors including Celgene, Novartis Oncology and Janssen and for the enthusiasm and dedication of all those involved in the

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

charity or who have campaigned and raised funds on its behalf. Without their support the charity would not be able to continue to offer hope and support to many thousands of MDS sufferers.

Edward Peel
Chair

Our purposes and activities

The Charity's principal activities during the year under review relate to the support of individuals suffering Myelodysplastic Syndrome ("MDS"), which is a rare blood cancer. The activities were previously carried on by a trust with the same name and were taken over by the company with effect from 1st April 2012.

The objects of the Charity are:

- (i) To relieve the sickness and preserve, promote and protect the health of sufferers of MDS in the United Kingdom through the provision of support, education and practical advice.
- (ii) To advance the education of the general public in the United Kingdom in all areas in relation to MDS.
- (iii) To promote and support scientific research into MDS and its treatment together with the care of MDS sufferers and those disposed to the development of MDS.

Achievements and performance

The Charity's main activities are the operation and maintenance of a website, the telephone helpline and e-mail support, regional and national group meetings as well as the Facebook page. MDS (UK) has continued to increase its advocacy work at both UK and European levels where it affects UK issues. All of these activities provide support and information to MDS sufferers and their families.

Achievements this year included: -

- The MDS UK Patient Research Project continues to receive completed questionnaires to be analysed at a later date.
- MDS UK promoted the fifth 'MDS World Awareness Day' in conjunction with international colleagues and the MDS Alliance. This event will continue to be marked in the future.

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

- The Charity has promoted its services and activities at multiple educational events throughout the UK, to groups of patients, nurses, physicians and pharma industry, through presentations and information stands.
- The MDS Patient Handbook collaboration project with Leukaemia CARE and Bloodwise (formerly Leukaemia and Lymphoma Research) has been completed and the booklet has been distributed to main hospitals.
- MDS UK continued to be actively involved at European and international level through organisations such as EMA (European Medicines Agency) ESH (European School of Haematology), EHA (European Haematology Association) and ASH (American Society of Haematology), together with other MDS overseas groups. Alliance activities have again increased, with MDS UK being a founder member and one of the core members due to experience and success in the UK. The formal co-operation will be of particular importance with regard to EMA licensing of new drugs.
- Of special note - MDS UK, via the MDS Alliance, has been elected to be part of the new European project on rare diseases called ERN's (European Reference Networks). The ERN dedicated to rare haematology conditions is called EuroBloodNet and the main purpose is to share best practice across Europe as well as facilitate cross-border healthcare and a wider access to clinical trials.
- The MDS website audience has significantly grown, attracting new users accessing the site via mobile devices and increasing the age range of people accessing information. MDS has opened a further information service, dedicated to providing patients and families information about clinical trials in MDS. The new service is proving equally popular with general haematologists, and the Principal Investigators who can struggle to recruit rare sub-types of patients.
- In terms of clinical trials, MDS UK has accepted to be co-applicants in two university hospital led trials, providing the patient perspective at all levels of the project.

Financial Review

The principal funding resources for the charity are by way of grants income, donations and fundraising. Total income for the year of £111,689 was 6% lower than the previous year (2015/16 - £118,455). A fall in donations of £33,344 compared to last year was partly compensated by a £26,000 increase in grants. Grants have been received from the pharmaceutical companies, and Celgene and Janssen. The grants are unrestricted and comply with the Code of Practice for the UK Pharmaceutical Industry.

Total expenditure for the year of £73,919 was £10,000 less than last year and under budget. This was largely due to the delay in the appointment of a full time project worker to be seconded from

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

Kings College. Some of this saving was offset by increased expenditure on development of our website which now plays a significant part in promoting and supporting the activities and objectives of the charity.

The surplus for the year of £37,770 has been added to unrestricted reserves that now amount to £315,743. During 2017/18 the directors will review the level of reserves with a view to supporting increased levels of activity. The aim will be to utilise the surplus funds to improve and upgrade the online facilities, databases and all types of communication methods, in order to increase frequency and quality of information output - as well as work speed and efficiency.

Reserves Policy and going concern

Reserves are needed to bridge the gap between the spending and receiving of income and to support the activities of the Charity in the event of a significant reduction in income. From time to time the directors review the required level of reserves. As referred to above, such a review will take place in 2017/18.

The directors are not aware of any material uncertainties relating to events or conditions that may cast significant doubt about the ability of the Charity to continue as a going concern and have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future.

Reference and administrative details

Charity number: 1145214
Company number: 07818480
Registered Office: Haematology - Bessemer Wing (Ground Floor), Kings
College Hospital, Denmark Hill, London SE5 9RS.

Our Advisors

Examiner: David King, FCA The Dell, Old Farm Rd, Hampton, TW12 3RJ
Bankers: CAF Bank Ltd
Co-Operative Bank Ltd
CCLA Investment Management Ltd
Scottish Widows Bank Ltd
Nationwide Building Society

Directors and trustees

The directors of the charitable company (the charity) are its trustees for the purpose of charity law. The trustees serving during the year and since the year end were as follows:

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

Rodney Taylor (until 3rd May, 2017)

Edward Peel (appointed Chair 28th April, 2017)

Sophie Wintrich

Fiona Pirilla

John Taylor

Don Barrett

Russell Cook

Chris Charlwood (Appointed 28th April, 2017)

Claudia Richards (Appointed 21st July, 2017)

Key management personnel:

Chief Executive: Sophie Wintrich

Structure, Governance and Management

Governing document

The entity is governed by its Memorandum and Articles of Association dated 21st October 2011. The charity is a company limited by guarantee. The members of the company who are directors are listed above. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the charity

Appointment of Directors

Existing directors propose new directors. The number of directors shall not be less than three and is not subject to any maximum.

Organisation

The board of directors administers the charity and normally meets quarterly. There is also a management committee which meets quarterly. A Chief Executive is appointed by the directors to manage the operations of the charity. To facilitate effective operations, the Chief Executive has delegated authority, within terms of delegation approved by the directors, for operational matters including finance and employment.

Risk Management

The directors have assessed the risks to which the charity is exposed and are satisfied that systems and procedures are in place to mitigate, where possible, those risks identified. The principal risk is that the level of activities undertaken by the charity is dependent on the level of funding received.

Directors' responsibilities in relation to the financial statements

The directors (who are also trustees for the purposes of charity law) are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March, 2017

Company law requires the directors to prepare the financial statements for each financial year. The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102) for Smaller Entities.

Under company law the directors must not approve the financial statements unless they give a true and fair view of the state of affairs of the company and of the incoming resources and outgoing resources of the company for that period

In preparing these financial statements, the directors are required to:

- (i) select suitable accounting policies and then apply them consistently;
- (ii) observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- (iii) make judgments and accounting estimates that are reasonable and prudent;
- (iv) prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The directors are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

By Order of the board of directors

Edward Peel (Chair)
Date



31/10/17

MDS UK PATIENT SUPPORT GROUP

Unaudited Statement of Financial Activities (Incorporating Income and Expenditure Account) for the year ended 31st March, 2017.

		2017 £	2016 £
	Note	Total	Total
Income from			
Donations and similar incoming resources	3	71,099	104,443
Grants	4	39,500	13,612
Investment income	5	1,090	400
Total income		<u>111,689</u>	<u>118,455</u>
Expenditure on			
Raising Funds	6	2,341	4,141
Charitable activities	7	71,279	78,821
Other	10	299	543
Total expenditure		<u>73,919</u>	<u>83,505</u>
Net income		37,770	34,950
Reconciliation of funds			
Total funds brought forward		277,973	243,023
Total funds carried forward		<u><u>315,743</u></u>	<u><u>277,973</u></u>

All amounts relate to continuing activities

The notes on pages 11 to 13 form part of these financial statements

MDS UK PATIENT SUPPORT GROUP

Unaudited Balance sheet As at 31st March 2017.

		2017 £	2016 £
	Note	Total	Total
Current assets:			
Debtors	12	2,534	12,582
Current asset investments	13	226,702	225,559
Cash at bank and in hand		88,003	55,078
Liabilities: Amounts falling due within one year			
Creditors and accruals	14	-1,496	-15,246
Total Net Assets		<u>315,743</u>	<u>277,973</u>
The Funds of the Charity			
Unrestricted income funds		315,743	277,973
Total funds		<u>315,743</u>	<u>277,973</u>

For the year ending 31st March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to obtain an audit of its financial statements in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act in respect of accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 9 to 13 were approved by the board of directors on the 30th October 2017 and authorised for issue and signed on its behalf by:



E Peel
Chair

Registered Company Number: 07818480
Registered Charity Number: 1145214

1) Accounting policies

Basis of accounting

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014.

Adoption of FRS 102 has not required any changes to the accounting policies and has not affected the reported financial position or financial performance.

Fund accounting

All funds are unrestricted and are available for use at the discretion of the directors in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Incoming resources

Income represents income attributable to the activities of the charity when:

- The Charity becomes entitled to the donation or similar income and any conditions for receipt are met:
- The directors are reasonably certain that they will receive it: and
- The directors are reasonably certain that the value can be reliably measured.

Resources expended

Liabilities are recognised as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Irrecoverable VAT is reported as part of the expenditure to which it relates.

Charitable activities

Costs of charitable activities includes expenditure incurred in the delivery of activities and services for beneficiaries and all the support costs as shown in note 9.

Governance costs

Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice. These costs include legal and professional fees and the costs of the AGM and governance meetings

Cash flow Statement

Due to its size, the charity is not required to present a Cash flow Statement under the Financial Reporting standards.

MDS UK PATIENT SUPPORT GROUP

Unaudited notes to the financial statements as at 31st March 2017

2) Directors Remuneration

The charity reimbursed Kings College Hospital Trust for emoluments of £35,625 and pension and NI contributions of £4,345 in respect of Sophie Wintrich, the Chief Executive

The other directors neither received or waived any emoluments.

The charity meets the expenses incurred by directors in carrying out their duties. During the year three directors had expenses met by the charity totaling £1,148 in respect of travel and subsistence. These are included in note 7.

3) Donations, legacies and similar incoming resources.

	2017 £	2016 £
Donations (including Gift Aid)	69,431	101,481
Event Income	-	2,962
Contribution to conferences	1,668	-
	<u>71,099</u>	<u>104,443</u>

4) Grants

Novartis	-	12,304
Celgene Limited	34,500	1,308
Janssen	5,000	-
	<u>39,500</u>	<u>13,612</u>

5) Investment Income

Bank Interest Received	<u>1,090</u>	<u>400</u>
------------------------	--------------	------------

6) Costs of raising funds

Advertising and promotion	<u>2,341</u>	<u>4,141</u>
---------------------------	--------------	--------------

7) Costs of activities for charitable objectives

Reimbursed staff costs	39,971	49,740
Website	11,220	758
Newsletter	300	11,241
Literature and Information Sheets	5,658	3,746
National Forums	4,058	5,746
Local Support Groups	865	1,088
Survey	629	-
Conference Participation	5,020	2,653
Travel and expenses	955	2,200
Support costs (Note 9)	2,603	1,649
	<u>71,279</u>	<u>78,821</u>

8) Staff Costs and Emoluments

The charity does not have any employees , but it paid Kings College Hospital Trust for the services of the Chief Executive.

MDS UK PATIENT SUPPORT GROUP

Unaudited notes to the financial statements as at 31st March 2017

	2017 £	2016 £
9) Support Costs		
Stationery and postage	351	476
Telephone and broadband	1,193	703
Office computer and software	848	288
Sundry expenses	211	182
	<u>2,603</u>	<u>1,649</u>
10) Other costs		
AGM & governance meetings	286	530
Legal Fees	13	13
	<u>299</u>	<u>543</u>
11) Taxation		
The company is a registered charity with no liability to tax arising in the year.		
12) Debtors		
Gift Aid Recoverable	2,534	-
Grant from Novartis	-	12,304
Prepayments	-	278
	<u>2,534</u>	<u>12,582</u>
13) Current asset investments		
Nationwide Building Society Deposit	75,644	75,209
CCLA Charities Deposit	75,479	75,188
Co-Op Instant Access	64	-
Scottish Widows Deposit	75,515	75,162
	<u>226,702</u>	<u>225,559</u>
14) Creditors		
Accruals	<u>1,496</u>	<u>15,246</u>

MDS UK PATIENT SUPPORT GROUP

INDEPENDENT EXAMINERS REPORT

I report on the accounts of MDS UK PATIENT SUPPORT GROUP for the year ended 31 March 2017, which are set out on pages 5 to 9. Your attention is drawn to the fact that the charity has prepared the accounts (financial statements) in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulation that has been withdrawn.

I understand that this has been done in order to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

Respective responsibilities of directors and examiner

The directors are responsible for the preparation of the accounts. The directors consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- Examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements:
 - a) to keep accounting records in accordance with section 386 of the Companies Act 2006;
 - b) to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 (section 130 of the Charities Act) and with the methods and principles of the Statement of Recommended Practice: Accounting and reporting by Charities

have not been met: or

- 2) to which in my opinion attention should be drawn in order to enable a proper understanding of the accounts to be reached.

David King
Chartered Accountant
The Dell
Old Farm Rd
Hampton, TW12 3RJ

Date